EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation

Asahi Oshima, Patrick W Serruys, Scot Garg, J William McEvoy, David A Wood, Torsten Doenst, David P Taggart, John D Puskas, Ajmal Shajahan, Faisal Sharif, Kotaro Miyashita, Akihiro Tobe und 10 weitere

EuroIntervention · 2026-02 · 22 (4) · 202-223

DOI: 10.4244/eij-d-25-00598 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift EuroIntervention, 2026-02. Verfasst von Asahi Oshima und 21 weiteren Autor:innen. Beteiligte Einrichtung: CORRIB Research Centre for Advanced Imaging and Core Laboratory, University of Galway, Galway, Ireland. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Myocardial Revascularization, Coronary Artery Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacological treatment remains vital in the effective management of atherosclerotic cardiovascular disease (ASCVD). Low-density lipoprotein (LDL) cholesterol-lowering therapies, such as statins, have consistently demonstrated robust efficacy in the primary and secondary prevention of cardiovascular events. The introduction of ezetimibe, bempedoic acid, and proprotein convertase subtilisin/kexin type 9 inhibitors have further strengthened the effectiveness of LDL cholesterol management, particularly in patients who are statin intolerant or who remain at high risk despite maximal tolerated statin therapy. In addition to managing LDL cholesterol, addressing residual lipid risk by targeting elevated triglyceride and lipoprotein(a) levels and low high-density lipoprotein cholesterol levels has emerged as a potentially important therapeutic consideration, as these are increasingly recognised as independent cardiovascular risk factors. Concurrently, inflammation is increasingly acknowledged as a significant contributor to atherogenesis and subsequent cardiovascular events. Clinical trials examining anti-inflammatory therapies, such as colchicine and interleukin-1β inhibitors (e.g., canakinumab), have demonstrated beneficial effects in reducing cardiovascular events independent of lipid modification. This narrative review provides an updated overview targeted specifically at physicians performing coronary artery bypass grafting or percutaneous coronary intervention. It summarises current evidence regarding established lipid-lowering therapies, emerging therapeutic approaches to address residual lipid risk, and the evolving role of anti-inflammatory interventions in the comprehensive management of ASCVD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anticholesteremic AgentsMyocardial RevascularizationCoronary Artery DiseaseHumansCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsRisk FactorsEzetimibeAnti-Inflammatory AgentsColchicineAntibodies, Monoclonal, Humanized

Substanzen

Anticholesteremic AgentsCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsEzetimibeAnti-Inflammatory AgentscanakinumabColchicineAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • CORRIB Research Centre for Advanced Imaging and Core Laboratory, University of Galway, Galway, Ireland.
  • Department of Cardiology, School of Medicine, University of Galway, Galway, Ireland and Cardiology Department, Galway University Hospital, Galway, Ireland.
  • Department of Cardiology, Royal Blackburn Hospital, Blackburn, United Kingdom.
  • School of Medicine, University of Central Lancashire, Preston, United Kingdom.
  • Division of Cardiology and National Institute for Prevention and Cardiovascular Health, National University of Ireland, Galway, Ireland.
  • Preventive Cardiology at the National Institute of Prevention and Cardiovascular Health (NIPC), University of Galway, Galway, Ireland.

Zitieren

APA

Oshima, A., Serruys, P. W., Garg, S., McEvoy, J. W., Wood, D. A., Doenst, T., Taggart, D. P., Puskas, J. D., Shajahan, A., Sharif, F., Miyashita, K., Tobe, A., Tsai, T. Y., Revaiah, P. C., Dunne, F., Mehran, R., Budoff, M. J., Kastelein, J. J., Stroes, E. S. G., …, & Onuma, Y. (2026). Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation. EuroIntervention, 22(4), 202-223. https://doi.org/10.4244/eij-d-25-00598

Vancouver

Oshima A, Serruys PW, Garg S, McEvoy JW, Wood DA, Doenst T, et al. Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation. EuroIntervention. 2026;22(4):202-223. doi:10.4244/eij-d-25-00598

BibTeX
@article{Oshima2026,
  author = {Oshima, Asahi and Serruys, Patrick W and Garg, Scot and McEvoy, J William and Wood, David A and Doenst, Torsten and Taggart, David P and Puskas, John D and Shajahan, Ajmal and Sharif, Faisal and Miyashita, Kotaro and Tobe, Akihiro and Tsai, Tsung-Ying and Revaiah, Pruthvi C and Dunne, Fidelma and Mehran, Roxana and Budoff, Matthew J and Kastelein, John J and Stroes, Eric S G and Khamis, Ramzi and Koenig, Wolfgang and Onuma, Yoshinobu},
  title = {Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation},
  journal = {EuroIntervention},
  year = {2026},
  volume = {22},
  number = {4},
  pages = {202--223},
  doi = {10.4244/eij-d-25-00598}
}
Kostenlos starten →